chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Tested positive again after completing the 5 days.; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive again after completing the 5 days.) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Allergy. Concomitant products included ESCITALOPRAM OXALATE (LEXAPRO) and BUPROPION HYDROCHLORIDE (WELLBUTRIN) for an unknown indication.    On 14-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-May-2022, the patient experienced COVID-19 (Tested positive again after completing the 5 days.). At the time of the report, COVID-19 (Tested positive again after completing the 5 days.) was resolving.            The co suspect drug was COVID-19 Treatment start date was 10-May-2022 and last date of administration was 14-May-2022.No, patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment. Yes, patient previously received a COVID-19 Vaccine. Treatment information was not provided. Device Date : 21May2022  Company comment: This spontaneous case concerns a 38-year-old female patient with no relevant medical history, who experienced the unexpected non-serious covid-19, seven months after receiving the mRNA-1273 vaccine as 3rd dose. The patient took medication(unspecified) for five days. It was reported that she tested positive again shortly after. The outcome was reported as resolving. Details of symptoms, clinical course, investigation reports and treatment were not provided. Details for first two vaccine doses was not provided. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 38-year-old female patient with no relevant medical history, who experienced the unexpected non-serious Covid-19, seven months after receiving the mRNA-1273 vaccine as 3rd dose. The patient took medication(unspecified) for five days. It was reported that she tested positive again shortly after. The outcome was reported as resolving. Details of symptoms, clinical course, investigation reports and treatment were not provided. Details for first two vaccine doses was not provided. The current pandemic situation of Covid-19 could be a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Erythema, mild pain and mild swelling to injection site. Applied ice to site with relief of symptoms.
Onset of chills transitioned to full body tremors; after lying flat body went numb from neck down to lower legs, muscle cramps in thighs and hands (index finger and thumb constricted, unable to straighten) during tremors. Abdominal cramps also occurred at this time. Shaking subsided after blankets and heating pad applied. Numbness eventually subsided leaving entire body woosy with nausea, headache, and lightheadedness/dizziness. Event lasted from 9:30 PM - 12:30 AM.
ED to Hosp-Admission  Current   9/3/2021 - present (5 days) Hospital Hypoxia  Principal problem Patient is an 78 y.o. male.    Medical history of right hip fracture status post fixation and revision and eventual infection for which she was recently discharged on IV cefepime 2 mg every 12 hours until September 17 by infectious disease he was at rehab getting IV antibiotics when he became short of breath and hypoxic which been going on for about 4 days they Covid swab him and was positive he was sent here to Hospital.  Here Hospital's Covid swab was negative he still feeling short of breath he is normally on 4 L nasal cannula he is on that now he initially was on a nonrebreather over at the rehab.  Incidentally they did find this right pneumothorax which was there previously they did discuss with CT surgery who did not feel like any intervention was needed they will continue to follow.  Patient denies any fevers chills nausea vomit abdominal pain dysuria polyuria diarrhea.
An intense, sharp pain in variety of areas (at different times).; Would have a bruise; From 30 minutes to an hour late, would have a bruise. Worst one was in pinky, like a vein burst.; Would be sore in that spot for a day or so. Worst one was in pinky.; Would have a bruise, one in the back of my head.; Would be sore in that spot for a day or so, one in the back of my head.; This is a spontaneous report from a contactable other healthcare professional, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL0142) via an intramuscular route of administration in the right arm on 29Dec2020 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included HBP (high blood pressure), depression and hyperlipidemia. The patient had no known allergies to medications, food, or other products. The patient received unspecified medication within two weeks of the COVID-19 vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Jan2021, the patient experienced an intense, sharp pain in variety of areas (at different times) and from 30 minutes to an hour late, she would have a bruise which would be sore in that spot for a day or so. The worst one was in the pinky, which felt like a vein burst and then one in the back of the head. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events an intense, sharp pain in variety of areas (at different times), bruise that would be sore in that spot for a day or so and worst one in pinky, and then one in the back of the head was resolved on an unknown date in 2021. The patient also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via an unspecified route of administration in the right arm on 19Jan2021 (at the age of 42-years-old) as a single dose for COVID-19 immunisation.   No follow-up attempts are needed. No further information is expected.
Information has been received from a licensed practical nurse concerning a male patient "in his 80's" who on an unspecified date was vaccinated with a dose of ZOSTAVAX (Merck) (lot # and expire date not reported), 0.65 ml, subcutaneously. On an unspecified date, the patient developed shingles on the face and in the scalp area. The patient sought medical attention by a dermatology visit. At the time of the report, the outcome of the patient was unknown. Follow up information received from the licensed practical nurse indicated that the patient was a 78 years old retired male, who on 26-MAR-2007 was vaccinated with a dose of ZOSTAVAX (Merck), 0.65 ml, subcutaneously. The nurse reported that the vaccine was not given at her office. The patient had a visit to the nurse's office on 23-SEP-2010 for pain on his scalp. On an unspecified date the patient saw a dermatologist; the dermatologist reported that the patient had an atypical shingles episode. On an unspecified date the patient recovered from pain. It was reported that "he did not have an adverse reaction to the vaccine; It's just that he probably got shingles despite it". The patient felt that "his illness was much less severe than it could have been without the vaccine". The patient's outcome was unknown. Follow-up information received from a completed questionnaire indicated that a rash did not occurred at the site of injection or elsewhere within 42 days of the vaccination. The onset date of the herpes zoster was reported as September 2010. Follow-up has been received from a licensed practitioner nurse who stated that there was no true adverse reaction. Additional information is not expected.
Myalgia & Arthralgia  Narrative:  achiness, chills, generalized joint pain and she used SL on 3/3/2021
Information has been received from a nurse concerning a 63 year old female with cholesterol high, blood pressure high, lupus, arthritis, seizures and allergy to dye who in January 1999, was vaccinated with a dose of PNEUMOVAX 23, IM, 0.5 ml. In January 1999, the patient experienced injection site reaction, including erythema, warmth and swelling of the whole upper arm. The patient was instructed to apply a corticosteroid cream and wrap a hot towel around the arm covered by a plastic, twice a day. The patient recovered within a few days. The patient sought medical attention and was seen by the physician. Additional information has been requested.
second one was worse than when she had COVID; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (second one was worse than when she had COVID) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (second one was worse than when she had COVID). At the time of the report, VACCINATION COMPLICATION (second one was worse than when she had COVID) outcome was unknown.            Concomitant medications were not reported. Treatment medications were not reported.   This case was linked to MOD-2022-460563 (Patient Link).
The effects lasted 48 hrs. Sore arm, tiredness, stiffness. But about a month later both shoulders became inflamed and I started experiencing shooting pains particularly in the left arm, but also in the left hip, left knee, both sides of the neck, and right arm. The pains in the left arm are at times consistent with brakes that can last 30 seconds to a few minutes.  More pains on the left side of the body than the right.  The tendons in both shoulders are tight due to inflammation. More so on the left shoulder. The effect is Shoulder impingement syndrome.
Approx 20 minutes after receiving vaccines clients mother c/o client nausea, sweaty, vomited small amount white milky substances, lips pale, yellow color, skin pale (dark complexion), very weak. Groggy but responsible to verbal and tactile stimuli. Oriented to persons name. VS 96.7-68-16-80/56. Respiration even and unlabored. Placed on exam table-supine with feet slightly elevated. 911 called, assessed by EMS 9:15AM. Condition improved within 15 minutes. Referred transport to DR via ambulance. 9:30AM child alert, talkative, up walking around. Denies pain, discomfort, no weakness, nausea. Mother staes she is back to normal.
Patient experienced tachycardia/anxious during 15 minute monitoring period after receiving first dose of Pfizer lot# EK9231. Patient was kept for an additional 15 minutes and improved within 10 minutes of the dose. Patient received vaccine on 1/15/2021.
No other AE details available at this time; Temperature excursion; This spontaneous report has been received from a registered nurse concerning a 12 months old patient of unknown gender. The patient's concurrent conditions, historical drugs, medical history and concomitant therapies were not reported.       On 11-DEC-2020, the patient was vaccinated with an improperly stored varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 ml,  Lot # T017688, expiration date 21-MAY-2022 for prophylaxis.  The temperature was reported to had been at -13.3°Celsius(C) for a period of 4 hours and 15 minutes.  No other adverse events details were available at this time.  There was digital data logger involved and no previous temperature excursion was reported.
Fever of 103.7 degrees, beginning at 6:00 PM, Fever 102.9 degrees at 06:05 AM next day, non responsive to antipyretics.
Swollen lymph nodes.  One floating one on collarbone.  Happy to send a video of the mass.
Information has been received from a medical assistant concerning her 5 year old daughter who on an unspecified date in 2000 was vaccinated with a dose of varicella virus vaccine live. On an unspecified date in Feb 2005, the patient developed pox on her arms, legs, back, and shoulder. She also had a fever and chills. As of 4/5/2005 the patient was recovered. Additional information has been requested.
Day of vaccine I got a bad headache. I suffer migraines and it was not a migraine, it was my whole head. I had nausea and vomiting that evening and the next day. Headache persisted the next day also. Got chills. Knees hurt. On 3rd day, was better.  then got congestion in nose and eyes, similar to allergic reaction to when I?m near a cat. Lasted two days. Knee still hurts and have been flushing for two weeks.
Describe the adverse event(s), treatment, and outcome(s), if any: (symptoms, signs, time course, etc.) Severe fatigue, unable to stand up for 3 months due to palpitations, dizzyness and syncope.  Chest pain, tightness and shortness of breath x 6 months, unable to walk or exercise.  Patient had COVID-19 infection 6 weeks confirmed with testing and then recvd immunization which precipitated the following symptoms within a few days, lasting for months and still on-going.  Result or outcome of adverse event(s): Unable to work- place on disability for the past several months, multiple physician visits, ER visits and consultation with neurology/cardiology with multiple testing showing non-specific findings- ultimately diagnosed with Stage 2 kidney failure, mast cell activation syndrome, chronic inflammatory response and POTS/Dysautonumia, chronic pain, GERD
Patient received Smallpox vaccination and Typhoid vaccination at 10 am on 8/9/05. At approximately 4pm patient noted hives to his face, was seen at ER at 5pm for facial rash. Diagnosed with probable allergic reaction to immunization. Benadryl 25mg q 6 hours prn ordered. Followed up on 8/10/05, hives no longer present. Only c/o was that of feeling tired.
the night of getting the vaccine I developed body aches, chills/feverish, arm pain, fatigue
Pt. is an 84-year-old female who presents to hospital with an increasing shortness of breath.  The patient has chronic obstructive pulmonary disease, for which she is on DuoNebs, Stiolto.  She reported increasing shortness of breath over the past several days.  She presented to Emergency Room.  She was diagnosed with coronavirus pneumonia and required increase in oxygen.  The patient has had no chest discomfort, palpitations, syncope, or abdominal pain.  7/31/2021 tested positive
pt recv vax in 1994 & pt immed devel a generalized rash on neck & trunk;tx w/epi;
tingling in both hands and feet; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP).  A female patient in her 50's received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PARAESTHESIA (non-serious), outcome "unknown", described as "tingling in both hands and feet". Additional information: A previous Pfizer colleague, female, in her 50s, shared that after receiving both doses of the COVID-19 vaccine, she experienced tingling in both hands and feet, more significantly after second dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
This literature marketed report was received from a physician regarding a male patient in his 70s. Patient was considered immunocompetent on the basis of an absence of immunodeficiency, history of opportunistic infection, autoimmune disease, systemic malignancy, or treatment with immunomodulatory medications. The patient received 3 doses of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (manufacturer unknown) at 0, 2 and 6 months in 2013 for prophylaxis (dosing details not reported). The vaccines were well tolerated by the patient and had no adverse effects. Prior to vaccination, patient had a mean of 12 new SCCs (87.5% SCC in situ, 6.25% well-differentiated SCC, and 6.25% SCC, keratoacanthoma-type) and 2.25 new BCCs per year. After vaccination, patient 1 developed a mean of 4.44 SCCs (100% SCC in situ) and 0 BCCs per year. This result represents a 62.5% reduction in sees and a 100% reduction in BCCs within the observation time of 16 months before and 16 months after the first dose of the qHPV vaccine (Therapeutic response unexpected). Outcome of the event was unknown. Causality of the event was considered to be related. This is one of 2 reports 1707USA006525 (Same literature link). Additional information has been requested. Sender's Comments: US-009507513-1707USA006525.
Pain/tenderness in armpit and inside/underside of arm; Pain/tenderness in armpit and inside/underside of arm; This is a spontaneous report from a non-contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the right arm on 09Apr2021 at 12:15 (at the age of 40-years-old) as a single dose for COVID-19 immunisation. Medical history included anxiety. The patient had known allergies to macadamia nuts and pineapple. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. On 14Apr2021 (also reported as five days post injection), the patient experienced pain/tenderness in armpit and inside/underside of arm which was lasting still twelve days post injection. The patient seemed to be improving. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of reported events. The clinical outcome of the events pain/tenderness in armpit and inside/underside of arm were resolved with sequelae (also reported as recovered with lasting effects) on 21Apr2021.  No follow-up attempts are possible. No further information is expected.
Erythema and induration 10 x 10mm over right arm.  No treatment except warm compress.
On 09/08/2022 I received my 5th dose of Pfizer Bivalent. My COVID-19 symptoms started on 10/01/2022 in the morning around 8:00AM. I had a sore throat, cough and chest congestions. I tested positive for COVID-19 on 10/02/2022. I called my doctor on 10/03/2022. My doctor who prescribed me with (PAXLOVID) for 5 days. After a month and a half on 12/09/2022. I developed Bronchitis. On 12/10/2022 my doctor prescribed me with doxycycline for 10 days and prednisone for days. I am still taking the medications as of today 12/13/2022.
Early evening soreness & swelling at injection site.  1am chills, followed by low grade fever of 100.1, then headache until noon.  General tiredness, headache and low grade fever 98.7 for remainder of day.  Next day all side effects were gone.
Fever of 103.5 for several hours. Chills, body aches, nausea and diarrhea
9:53 am - 5 minutes after receiving vaccine, pt reports feeling chills and palpitations.  10:04 am evaluated by EMS BP 122/87 P 78 10:55 am pt requesting to be transported to Hosp for evaluations.
10 hours post vaccination, she felt tightness in chest and felt slightly wheezy. 16 hours post test she was wheezing, taking shallow breaths, and felt like her throat was constricted. Shallow breaths only. Symptoms slowly dissipated. She returned to normal over the next two days post reaction.
Vesicles grouped ,erythematous base @ site of injection, approximately 12 days post shot.
Expired vaccine used; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 24-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.  The box of vials was received on 14-Oct-2021. It was frozen when it was received and was immediately placed in the clinic vaccine freezer. The vials remained frozen until the date of use and were thawed in the vaccine refrigerator prior to use. The vials remained in the refrigerator between uses and each vial was discarded after the final appointment of the day. Only 1 vial was used per day between the hours of 8:00am to 4:00pm.
This spontaneous report was received from a medical assistant refers to an unknown number of patients of unknown age. The medical history, concurrent conditions and concomitant medications were not reported. On an unknown date, the patients were vaccinated with improperly stored ROTATEQ lot # L027067, 04-JUN-2017 exposed to 0.4 degree centigrade for 344 hours, L029617 19-MAY-2017 exposed to 0.3 degree centigrade for 326 hours, lot L033545 30-MAY-2017 exposed to 34.1F for 132 hours, L027076 25-MAY-201 exposed to 0.7 degree centigrade for 177 hours, M004508 29-JUN-2017 exposed to 30F for 408 hours, M014318 30-SEP-2017 to 30F for 210 hours. No adverse effects were reported. There was no prior excursions. Additional information has been requested.